Kelly E Dunn1, Patrick H Finan2, D Andrew Tompkins2, Eric C Strain2. 1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, United States. Electronic address: kdunn9@jhmi.edu. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, United States.
Abstract
BACKGROUND: Opioid use disorder (OUD) is a significant public health problem, and opioid maintenance treatment (OMT) on methadone or buprenorphine is a common approach. This study characterized sleep impairment in patients maintained on methadone or buprenorphine, and evaluated its association with psychiatric and medical comorbidities. METHODS: Participants (N=185) maintained on methadone (N=125) or buprenorphine (N=60) for OUD completed the Medical Outcomes Study Sleep Scale (MOS) to provide a point-prevalence assessment of sleep impairment. Measures of lifetime problems and current functioning were also examined and compared as both a function of OMT and level of sleep impairment. RESULTS: Participants reported high levels of sleep impairment on the MOS, including not getting the amount of sleep they needed (42.9%), not sleeping enough to feel rested (39.6%) and trouble falling asleep (23.3%) or falling back asleep after waking (25.8%). Few differences were observed between OMT groups, and psychiatric dysfunction emerged as the most robust predictor of sleep impairment ratings. Patients with sleep impairment, independent of OMT medications, also reported current opioid withdrawal, psychiatric impairment, negative affect, and pain. CONCLUSIONS: Results demonstrate substantial and clinically-significant impairments in sleep that are associated with a variety of current problems that could impact OMT outcomes and decrease quality of life. Outcomes support the development of methods to improve sleep in OMT patients, and to examine the degree to which sleep improvements may be associated with improvements in mood and other health-related measures.
BACKGROUND: Opioid use disorder (OUD) is a significant public health problem, and opioid maintenance treatment (OMT) on methadone or buprenorphine is a common approach. This study characterized sleep impairment in patients maintained on methadone or buprenorphine, and evaluated its association with psychiatric and medical comorbidities. METHODS:Participants (N=185) maintained on methadone (N=125) or buprenorphine (N=60) for OUD completed the Medical Outcomes Study Sleep Scale (MOS) to provide a point-prevalence assessment of sleep impairment. Measures of lifetime problems and current functioning were also examined and compared as both a function of OMT and level of sleep impairment. RESULTS:Participants reported high levels of sleep impairment on the MOS, including not getting the amount of sleep they needed (42.9%), not sleeping enough to feel rested (39.6%) and trouble falling asleep (23.3%) or falling back asleep after waking (25.8%). Few differences were observed between OMT groups, and psychiatric dysfunction emerged as the most robust predictor of sleep impairment ratings. Patients with sleep impairment, independent of OMT medications, also reported current opioid withdrawal, psychiatric impairment, negative affect, and pain. CONCLUSIONS: Results demonstrate substantial and clinically-significant impairments in sleep that are associated with a variety of current problems that could impact OMT outcomes and decrease quality of life. Outcomes support the development of methods to improve sleep in OMTpatients, and to examine the degree to which sleep improvements may be associated with improvements in mood and other health-related measures.
Authors: Kelly S Barth; Megan Moran-Santa Maria; Katie Lawson; Stephanie Shaftman; Kathleen T Brady; Sudie E Back Journal: Am J Addict Date: 2013-05-15
Authors: Claudia M Campbell; Sara C Bounds; Hiroto Kuwabara; Robert R Edwards; James N Campbell; Jennifer A Haythornthwaite; Michael T Smith Journal: Pain Med Date: 2013-09-18 Impact factor: 3.750
Authors: Celeste M Caviness; Bradley J Anderson; Marcel A de Dios; Megan Kurth; Michael Stein Journal: Drug Alcohol Depend Date: 2012-07-31 Impact factor: 4.492
Authors: Stephen R Baldassarri; Mark Beitel; Andrey Zinchuk; Nancy S Redeker; David E Oberleitner; Lindsay M S Oberleitner; Danilo Carrasco; Lynn M Madden; Nathan Lipkind; David A Fiellin; Lori A Bastian; Kevin Chen; H Klar Yaggi; Declan T Barry Journal: Sleep Breath Date: 2020-06-17 Impact factor: 2.816
Authors: Kelly E Dunn; Andrew S Huhn; Cecilia L Bergeria; Cassandra D Gipson; Elise M Weerts Journal: J Pharmacol Exp Ther Date: 2019-08-07 Impact factor: 4.030
Authors: Ilene M Rosen; R Nisha Aurora; Douglas B Kirsch; Kelly A Carden; Raman K Malhotra; Kannan Ramar; Fariha Abbasi-Feinberg; David A Kristo; Jennifer L Martin; Eric J Olson; Carol L Rosen; James A Rowley; Anita V Shelgikar Journal: J Clin Sleep Med Date: 2019-11-15 Impact factor: 4.062
Authors: Lais F Berro; C Austin Zamarripa; Joseph T Talley; Kevin B Freeman; James K Rowlett Journal: Addict Behav Date: 2022-07-22 Impact factor: 4.591
Authors: Jeremiah W Bertz; David H Epstein; David Reamer; William J Kowalczyk; Karran A Phillips; Ashley P Kennedy; Michelle L Jobes; Greg Ward; Barbara A Plitnick; Mariana G Figueiro; Mark S Rea; Kenzie L Preston Journal: J Subst Abuse Treat Date: 2019-08-14
Authors: Jennifer D Ellis; Jami L Mayo; Charlene E Gamaldo; Patrick H Finan; Andrew S Huhn Journal: J Clin Sleep Med Date: 2022-02-01 Impact factor: 4.062
Authors: Patrick H Finan; Chung Jung Mun; David H Epstein; William J Kowalczyk; Karran A Phillips; Daniel Agage; Michael T Smith; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2019-11-18 Impact factor: 4.852